SG10201500048SA - Compositions and methods for treating glioblastoma gbm - Google Patents
Compositions and methods for treating glioblastoma gbmInfo
- Publication number
- SG10201500048SA SG10201500048SA SG10201500048SA SG10201500048SA SG10201500048SA SG 10201500048S A SG10201500048S A SG 10201500048SA SG 10201500048S A SG10201500048S A SG 10201500048SA SG 10201500048S A SG10201500048S A SG 10201500048SA SG 10201500048S A SG10201500048S A SG 10201500048SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- treating glioblastoma
- gbm
- glioblastoma gbm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28222810P | 2010-01-05 | 2010-01-05 | |
| US28224810P | 2010-01-07 | 2010-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500048SA true SG10201500048SA (en) | 2015-03-30 |
Family
ID=44305240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201500048SA SG10201500048SA (en) | 2010-01-05 | 2011-01-05 | Compositions and methods for treating glioblastoma gbm |
| SG2012049573A SG182366A1 (en) | 2010-01-05 | 2011-01-05 | Compositions and methods for treating glioblastoma gbm |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012049573A SG182366A1 (en) | 2010-01-05 | 2011-01-05 | Compositions and methods for treating glioblastoma gbm |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130209450A1 (en) |
| EP (1) | EP2521777B1 (en) |
| JP (2) | JP6151515B2 (en) |
| KR (1) | KR101810257B1 (en) |
| AU (1) | AU2011204407B2 (en) |
| CA (1) | CA2786377C (en) |
| MX (1) | MX338931B (en) |
| NZ (1) | NZ601325A (en) |
| SG (2) | SG10201500048SA (en) |
| WO (1) | WO2011083466A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| EP1436313B1 (en) | 2001-10-19 | 2010-09-22 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| MX2009001157A (en) | 2006-07-31 | 2009-03-20 | Vascular Biogenics Ltd | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia. |
| JP5752599B2 (en) | 2008-11-06 | 2015-07-22 | ヴァスキュラー バイオジェニックス リミテッド | Oxidized lipid compounds and uses thereof |
| DK2521776T3 (en) | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
| AU2011204407B2 (en) | 2010-01-05 | 2015-05-07 | Vascular Biogenics Ltd. | Compositions and methods for treating glioblastoma GBM |
| EP3441089B1 (en) * | 2012-10-17 | 2022-12-14 | Vascular Biogenics Ltd. | Treatment methods using adenovirus |
| WO2014118643A2 (en) | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| CN110237447B (en) | 2013-09-27 | 2021-11-02 | 梅维昂医疗系统股份有限公司 | Particle therapy system |
| US9962560B2 (en) | 2013-12-20 | 2018-05-08 | Mevion Medical Systems, Inc. | Collimator and energy degrader |
| US10675487B2 (en) | 2013-12-20 | 2020-06-09 | Mevion Medical Systems, Inc. | Energy degrader enabling high-speed energy switching |
| US9661736B2 (en) | 2014-02-20 | 2017-05-23 | Mevion Medical Systems, Inc. | Scanning system for a particle therapy system |
| JP6717825B2 (en) | 2014-11-26 | 2020-07-08 | バスキュラー バイオジェニックス リミテッド | Oxidized lipids and methods for treating or preventing fibrosis |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| US10786689B2 (en) | 2015-11-10 | 2020-09-29 | Mevion Medical Systems, Inc. | Adaptive aperture |
| US20170273926A1 (en) * | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
| EP3481503B1 (en) | 2016-07-08 | 2021-04-21 | Mevion Medical Systems, Inc. | Treatment planning |
| NZ752894A (en) | 2016-10-06 | 2023-05-26 | Orbus Therapeutics Inc | Formulations for administration of eflornithine |
| US11103730B2 (en) | 2017-02-23 | 2021-08-31 | Mevion Medical Systems, Inc. | Automated treatment in particle therapy |
| EP3645111A1 (en) | 2017-06-30 | 2020-05-06 | Mevion Medical Systems, Inc. | Configurable collimator controlled using linear motors |
| CN111356480A (en) | 2017-10-20 | 2020-06-30 | 脉管生物生长有限公司 | Diagnostic methods for anti-angiogenic agent therapy |
| JP7311620B2 (en) | 2019-03-08 | 2023-07-19 | メビオン・メディカル・システムズ・インコーポレーテッド | Collimators and energy degraders for particle therapy systems |
| AU2020234098A1 (en) | 2019-03-13 | 2021-09-16 | Vascular Biogenics Ltd. | Methods of anti-tumor therapy |
| CN113710265A (en) | 2019-04-12 | 2021-11-26 | 脉管生物生长有限公司 | Method of antitumor therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2272820C (en) | 1996-11-20 | 2012-09-11 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US6204055B1 (en) * | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
| IL130608A0 (en) | 1999-06-23 | 2000-06-01 | Compugen Ltd | Novel nucleic and amino acid sequence |
| US6867022B1 (en) | 2000-01-21 | 2005-03-15 | Regents Of The University Of Michigan | Replication deficient adenovirus vectors and methods of making and using them |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8039261B2 (en) * | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| DK2186530T3 (en) | 2000-11-17 | 2013-07-29 | Vascular Biogenics Ltd | Promoters exhibiting endothelial cell specificity and methods for their use |
| US20100282634A1 (en) | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| US7067649B2 (en) | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| KR100453877B1 (en) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR |
| EP1436313B1 (en) | 2001-10-19 | 2010-09-22 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| JP2008508899A (en) | 2004-08-09 | 2008-03-27 | メルク エンド カムパニー インコーポレーテッド | Adenovirus vector composition |
| US20090232808A1 (en) | 2005-01-28 | 2009-09-17 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| EP1942900B1 (en) | 2005-10-06 | 2015-06-03 | Merck Sharp & Dohme Corp. | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases |
| MX2009001157A (en) | 2006-07-31 | 2009-03-20 | Vascular Biogenics Ltd | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia. |
| AU2011204407B2 (en) | 2010-01-05 | 2015-05-07 | Vascular Biogenics Ltd. | Compositions and methods for treating glioblastoma GBM |
| DK2521776T3 (en) | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
| SG182490A1 (en) | 2010-01-12 | 2012-08-30 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
| EP3441089B1 (en) | 2012-10-17 | 2022-12-14 | Vascular Biogenics Ltd. | Treatment methods using adenovirus |
-
2011
- 2011-01-05 AU AU2011204407A patent/AU2011204407B2/en active Active
- 2011-01-05 MX MX2012007850A patent/MX338931B/en active IP Right Grant
- 2011-01-05 SG SG10201500048SA patent/SG10201500048SA/en unknown
- 2011-01-05 KR KR1020127020567A patent/KR101810257B1/en active IP Right Grant
- 2011-01-05 NZ NZ601325A patent/NZ601325A/en unknown
- 2011-01-05 SG SG2012049573A patent/SG182366A1/en unknown
- 2011-01-05 JP JP2012547587A patent/JP6151515B2/en not_active Expired - Fee Related
- 2011-01-05 WO PCT/IL2011/000009 patent/WO2011083466A1/en active Application Filing
- 2011-01-05 CA CA2786377A patent/CA2786377C/en active Active
- 2011-01-05 US US13/520,452 patent/US20130209450A1/en not_active Abandoned
- 2011-01-05 EP EP11731735.4A patent/EP2521777B1/en active Active
-
2013
- 2013-03-14 US US13/826,303 patent/US10369196B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001588A patent/JP2016128440A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR101810257B1 (en) | 2017-12-18 |
| CA2786377A1 (en) | 2011-07-14 |
| WO2011083466A1 (en) | 2011-07-14 |
| JP2016128440A (en) | 2016-07-14 |
| CA2786377C (en) | 2018-02-27 |
| NZ601325A (en) | 2014-09-26 |
| AU2011204407A1 (en) | 2012-08-09 |
| KR20120120942A (en) | 2012-11-02 |
| MX338931B (en) | 2016-05-06 |
| US20130303595A1 (en) | 2013-11-14 |
| JP6151515B2 (en) | 2017-06-21 |
| EP2521777A4 (en) | 2014-04-02 |
| US20130209450A1 (en) | 2013-08-15 |
| JP2013516456A (en) | 2013-05-13 |
| US10369196B2 (en) | 2019-08-06 |
| SG182366A1 (en) | 2012-08-30 |
| MX2012007850A (en) | 2012-12-05 |
| AU2011204407B2 (en) | 2015-05-07 |
| EP2521777A1 (en) | 2012-11-14 |
| EP2521777B1 (en) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201500048SA (en) | Compositions and methods for treating glioblastoma gbm | |
| HK1246715A1 (en) | Compositions and methods for targeted thermomodulation | |
| HK1185623A1 (en) | Methods and compositions for treating hemophilia | |
| HK1201475A1 (en) | Methods and compositions for treating pain | |
| HK1214521A1 (en) | Compositions and methods for treating proteinopathies | |
| EP2655334A4 (en) | Compositions and methods useful for treating diseases | |
| IL269166A (en) | Methods and compositions for treating inflammation | |
| EP2603199A4 (en) | Compositions and methods for treating cardiovascular disease | |
| EP2643045A4 (en) | Therapeutic methods and compositions for solid delivery | |
| EP2603202A4 (en) | Compositions and methods for treatment of taupathy | |
| EP2624702A4 (en) | Anti-biofilm compositions and methods for using | |
| EP2575825A4 (en) | Compositions and methods for treating depression | |
| SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
| EP2590674A4 (en) | Compositions and methods for treating influenza | |
| EP2637505A4 (en) | Compositions and methods for treating erectile dysfunction | |
| EP2632460A4 (en) | Compositions and methods for treating tuberculosis | |
| HK1183766A1 (en) | Compositions and methods for treating bruises | |
| IL225483A0 (en) | Compositions and methods for treating neoplasia | |
| EP2582384A4 (en) | Compositions and methods for treating cancer | |
| EP2537031A4 (en) | Compositions and methods for treating cancer | |
| PL2606032T3 (en) | Composition and methods for treating glioblastomas | |
| EP2600864A4 (en) | Compositions and methods for treating inflammatory diseases | |
| EP2718427A4 (en) | Compositions and methods for glioblastoma treatment | |
| EP2714082A4 (en) | Compositions and methods for treating pain | |
| EP2654793A4 (en) | Methods and compositions for wound treatment |